Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes

Cancer Immunology, Immunotherapy

Volumn 65, Issue 11, 2016, Pages 1377-1393

  Gloger, Andreas ^a   Ritz, Danilo ^b   Fugmann, Tim ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

Author keywords

HLA; Immunocapture; Immunopeptidome; Mass spectrometry; Melanoma; Tumor associated antigen

Indexed keywords

AMINO ACID; EPITOPE; HLA ANTIGEN CLASS 1; PEPTIDE; PEPTIDOME; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG; HLA ANTIGEN; PROTEIN BINDING; TUMOR ANTIGEN;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FM 82 CELL LINE; FM 93/2 CELL LINE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MEL 624 CELL LINE; MELANOMA CELL LINE; MEWO CELL LINE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SK MEL 5 CELL LINE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPITOPE MAPPING; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ALLELES; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; MASS SPECTROMETRY; MELANOMA; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84986242733     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1897-3     Document Type: Article

References (38)

1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. doi:10.1038/nrc3239
2. Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56–61. doi:10.1126/science.aaa8172
3. Probst P, Neri D (2014) Immunocytokines for cancer therapy. Forum Immunopathol Dis Therap 5(1):83–99. doi:10.1615/ForumImmunDisTher.2015014013
4. Kontermann RE, Brinkmann U (2015) Bispecific antibodies. Drug Discov Today 20(7):838–847. doi:10.1016/j.drudis.2015.02.008
5. Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62–68. doi:10.1126/science.aaa4967
6. June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7(280):280ps7. doi:10.1126/scitranslmed.aaa3643
7. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11(9):509–524. doi:10.1038/nrclinonc.2014.111
8. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747–752. doi:10.1038/nm.3161
9. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D (2002) Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 98(3):409–414
10. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebaek E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72(7):1642–1650. doi:10.1158/0008-5472.CAN-11-2614
11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, PedBrain I, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR, Australian Pancreatic Cancer Genome I, Consortium IBC, Consortium IM-S (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421. doi:10.1038/nature12477
12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546–1558. doi:10.1126/science.1235122
13. Hadrup SR, Schumacher TN (2010) MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother 59(9):1425–1433. doi:10.1007/s00262-010-0824-2
14. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284):94–96
15. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA (2015) Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350(6266):1387–1390. doi:10.1126/science.aad1253
16. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6(254):254ra128. doi:10.1126/scitranslmed.3008918
17. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264(5159):716–719
18. Jarmalavicius S, Welte Y, Walden P (2012) High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J Biol Chem 287(40):33401–33411. doi:10.1074/jbc.M112.358903
19. Pritchard AL, Hastie ML, Neller M, Gorman JJ, Schmidt CW, Hayward NK (2015) Exploration of peptides bound to MHC class I molecules in melanoma. Pigment Cell Melanoma Res 28(3):281–294. doi:10.1111/pcmr.12357
20. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA (2013) The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteom 12(7):1829–1843. doi:10.1074/mcp.M112.024810
21. Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M (2015) Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteom 14(3):658–673. doi:10.1074/mcp.M114.042812
22. Ritz D, Gloger A, Weide B, Garbe C, Neri D, Fugmann T (2016) High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera. Proteomics 16(10):1570–1580. doi:10.1002/pmic.201500445
23. Pawelec G, Marsh SG (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55(6):623–627. doi:10.1007/s00262-005-0117-3
24. Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH (2012) Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 35(2):131–141. doi:10.1097/CJI.0b013e31824300c7
25. Toebes M, Rodenko B, Ovaa H, Schumacher TN (2009) Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol. doi:10.1002/0471142735.im1816s87
26. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367–1372. doi:10.1038/nbt.1511
27. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Roder G, Peters B, Sette A, Lund O, Buus S (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2(8):e796. doi:10.1371/journal.pone.0000796
28. Boegel S, Lower M, Bukur T, Sahin U, Castle JC (2014) A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology 3(8):e954893. doi:10.4161/21624011.2014.954893
29. Thomsen MC, Nielsen M (2012) Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion. Nucleic Acids Res 40(Web Server issue):W281–W287. doi:10.1093/nar/gks469
30. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue):D945–D950. doi:10.1093/nar/gkq929
31. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14(1):9–20
32. Rapin N, Hoof I, Lund O, Nielsen M (2008) MHC motif viewer. Immunogenetics 60(12):759–765. doi:10.1007/s00251-008-0330-2
33. Rasmussen M, Harndahl M, Stryhn A, Boucherma R, Nielsen LL, Lemonnier FA, Nielsen M, Buus S (2014) Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J Immunol 193(10):4790–4802. doi:10.4049/jimmunol.1401689
34. Apps R, Meng Z, Del Prete GQ, Lifson JD, Zhou M, Carrington M (2015) Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. J Immunol 194(8):3594–3600. doi:10.4049/jimmunol.1403234
35. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199. doi:10.1056/NEJMoa1406498
36. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74. doi:10.1126/science.aaa4971
37. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, Pawelec G (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30(15):1835–1841. doi:10.1200/JCO.2011.40.2271
38. Haen SP, Rammensee HG (2013) The repertoire of human tumor-associated epitopes–identification and selection of antigens and their application in clinical trials. Curr Opin Immunol 25(2):277–283. doi:10.1016/j.coi.2013.03.007